C-Reactive Protein Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Description
Growth Factors of C-reactive protein (CRP) testing Market
The global C-reactive protein (CRP) testing market is projected to witness steady growth due to the rising prevalence of chronic diseases, increasing adoption of point-of-care (POC) testing, and growing awareness about the role of CRP as an inflammation marker. According to Fortune Business Insights, the market was valued at USD 2.55 billion in 2025, expected to grow to USD 2.69 billion in 2026, and is forecasted to reach USD 3.95 billion by 2034, registering a CAGR of 4.9% during the forecast period. North America dominated the market in 2025 with a share of 34.5%, driven by high disease burden, advanced healthcare infrastructure, and growing preference for CRP point-of-care tests.
CRP is a non-specific marker of inflammation and plays a critical role in predicting cardiovascular risks, including heart attack and stroke. It is also used in diagnosing chronic conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases. The market growth is further supported by technological advancements in CRP testing instruments and kits, including POC solutions.
Market Dynamics
Drivers
The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders, has driven the demand for CRP testing. According to CDC data from 2022, approximately 20.1 million adults in the U.S. suffer from coronary artery disease, with an estimated 805,000 heart attacks occurring annually. The rising patient population and growing focus on preventive healthcare have fueled the adoption of CRP testing globally.
Another major driver is the development of point-of-care CRP tests, which aid clinicians in reducing antibiotic prescriptions and improving diagnostic efficiency. For instance, research published in the British Journal of General Practice (2022) highlighted the use of CRP POC testing for acute respiratory infections to minimize unnecessary antibiotic use. Companies such as Bloom Diagnostics and LumiraDx are launching advanced POC CRP tests to address this growing need.
Trends
The market is witnessing a growing focus on technologically advanced testing kits and instruments. The immunoturbidimetric assay segment dominated the market in 2026 with a 75.09% share, due to widespread product availability and strong adoption in clinical laboratories. High-sensitivity CRP (hs-CRP) testing is gaining traction for cardiovascular risk assessment. Additionally, the increasing use of POC tests in community healthcare settings is expected to drive growth further.
Restraints
CRP is a non-specific inflammation marker, which limits its use as a standalone diagnostic test. Alternative diagnostics, such as coronary CT angiography, electrocardiography (ECG), and stress tests, provide more accurate disease-specific results. The availability of these alternatives may slow the adoption of CRP tests to some extent.
Market Segmentation
By Product: The market is divided into reagents & kits and instruments. Reagents & kits dominated with a 73.61% share in 2026, driven by high testing volumes and strong offerings from key players like Abbott and LumiraDx. The instruments segment is expected to grow due to increasing regulatory approvals for innovative devices, such as the ProciseDx instrument approved by the U.S. FDA in 2022.
By Assay Type: The market is segmented into immunoturbidimetric assay, ELISA, CLIA, and others. Immunoturbidimetric assays lead due to ease of use and widespread adoption, while ELISA and CLIA-based assays are steadily growing, particularly for chronic disease detection.
By Detection Range: Conventional CRP dominated with an 89.96% share in 2026, primarily for chronic and autoimmune disease monitoring. High-sensitivity CRP tests are increasingly used for cardiovascular risk assessment.
By Setting: Laboratory testing led with 75.84% share in 2026, attributed to precise and comprehensive analysis. POC testing is expected to grow significantly in resource-limited or primary care settings.
By End-User: Diagnostic laboratories dominate due to the increasing number of tests for chronic disease management, while hospitals and clinics are expected to witness strong growth due to rising hospitalizations and clinical demand.
Regional Insights
North America: USD 0.88B (2025), USD 0.85B (2026); dominated by U.S. chronic disease burden, innovation, and clinical research.
Europe: UK USD 0.12B, Germany USD 0.18B (2026); growth supported by regulatory approvals, CE-marked products, and rising adoption for autoimmune disease monitoring.
Asia Pacific: Japan USD 0.15B, China USD 0.22B, India USD 0.11B (2026); driven by chronic disease prevalence, public health initiatives, and strategic partnerships such as FIND-SD Biosensor collaborations.
Latin America & Middle East/Africa: Moderate growth due to improving healthcare infrastructure and adoption of rapid diagnostic tests.
Key Industry Players
Prominent companies in the market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Getein Biotech, Randox Laboratories, Boditech Med, and LumiraDx. Market players are focusing on research and development, new product launches, and expanding POC offerings. For instance, Abbott’s acquisition of Alere Inc. in 2016 expanded its POC testing portfolio.
Notable developments include Siemens FDA clearance for CardioPhase hs-CRP test (Dec 2022) and Boditech Med MoU for North American market entry (Mar 2022).
Conclusion
The global C-reactive protein testing market is projected to grow from USD 2.55 billion in 2025 to USD 3.95 billion by 2034, supported by rising chronic disease prevalence, increasing adoption of POC tests, and continuous innovation in assay technologies. Despite limitations due to alternative diagnostics, CRP testing remains a vital tool for inflammation monitoring, cardiovascular risk prediction, and improving patient management worldwide.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 4.9% from 2026-2034
Unit Value (USD billion)
Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region
By Product Reagents & Kits
Instruments
By Assay Type Chemiluminescence Immunoassay (CLIA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Immunoturbidimetric Assay
Others
By Detection Range Conventional CRP
hs-CRP
By Setting
Laboratory Testing
Point-of-Care (POC) Testing
By End User Hospitals & Clinics
Diagnostic Laboratories
Others
By Region North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
The global C-reactive protein (CRP) testing market is projected to witness steady growth due to the rising prevalence of chronic diseases, increasing adoption of point-of-care (POC) testing, and growing awareness about the role of CRP as an inflammation marker. According to Fortune Business Insights, the market was valued at USD 2.55 billion in 2025, expected to grow to USD 2.69 billion in 2026, and is forecasted to reach USD 3.95 billion by 2034, registering a CAGR of 4.9% during the forecast period. North America dominated the market in 2025 with a share of 34.5%, driven by high disease burden, advanced healthcare infrastructure, and growing preference for CRP point-of-care tests.
CRP is a non-specific marker of inflammation and plays a critical role in predicting cardiovascular risks, including heart attack and stroke. It is also used in diagnosing chronic conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases. The market growth is further supported by technological advancements in CRP testing instruments and kits, including POC solutions.
Market Dynamics
Drivers
The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders, has driven the demand for CRP testing. According to CDC data from 2022, approximately 20.1 million adults in the U.S. suffer from coronary artery disease, with an estimated 805,000 heart attacks occurring annually. The rising patient population and growing focus on preventive healthcare have fueled the adoption of CRP testing globally.
Another major driver is the development of point-of-care CRP tests, which aid clinicians in reducing antibiotic prescriptions and improving diagnostic efficiency. For instance, research published in the British Journal of General Practice (2022) highlighted the use of CRP POC testing for acute respiratory infections to minimize unnecessary antibiotic use. Companies such as Bloom Diagnostics and LumiraDx are launching advanced POC CRP tests to address this growing need.
Trends
The market is witnessing a growing focus on technologically advanced testing kits and instruments. The immunoturbidimetric assay segment dominated the market in 2026 with a 75.09% share, due to widespread product availability and strong adoption in clinical laboratories. High-sensitivity CRP (hs-CRP) testing is gaining traction for cardiovascular risk assessment. Additionally, the increasing use of POC tests in community healthcare settings is expected to drive growth further.
Restraints
CRP is a non-specific inflammation marker, which limits its use as a standalone diagnostic test. Alternative diagnostics, such as coronary CT angiography, electrocardiography (ECG), and stress tests, provide more accurate disease-specific results. The availability of these alternatives may slow the adoption of CRP tests to some extent.
Market Segmentation
By Product: The market is divided into reagents & kits and instruments. Reagents & kits dominated with a 73.61% share in 2026, driven by high testing volumes and strong offerings from key players like Abbott and LumiraDx. The instruments segment is expected to grow due to increasing regulatory approvals for innovative devices, such as the ProciseDx instrument approved by the U.S. FDA in 2022.
By Assay Type: The market is segmented into immunoturbidimetric assay, ELISA, CLIA, and others. Immunoturbidimetric assays lead due to ease of use and widespread adoption, while ELISA and CLIA-based assays are steadily growing, particularly for chronic disease detection.
By Detection Range: Conventional CRP dominated with an 89.96% share in 2026, primarily for chronic and autoimmune disease monitoring. High-sensitivity CRP tests are increasingly used for cardiovascular risk assessment.
By Setting: Laboratory testing led with 75.84% share in 2026, attributed to precise and comprehensive analysis. POC testing is expected to grow significantly in resource-limited or primary care settings.
By End-User: Diagnostic laboratories dominate due to the increasing number of tests for chronic disease management, while hospitals and clinics are expected to witness strong growth due to rising hospitalizations and clinical demand.
Regional Insights
North America: USD 0.88B (2025), USD 0.85B (2026); dominated by U.S. chronic disease burden, innovation, and clinical research.
Europe: UK USD 0.12B, Germany USD 0.18B (2026); growth supported by regulatory approvals, CE-marked products, and rising adoption for autoimmune disease monitoring.
Asia Pacific: Japan USD 0.15B, China USD 0.22B, India USD 0.11B (2026); driven by chronic disease prevalence, public health initiatives, and strategic partnerships such as FIND-SD Biosensor collaborations.
Latin America & Middle East/Africa: Moderate growth due to improving healthcare infrastructure and adoption of rapid diagnostic tests.
Key Industry Players
Prominent companies in the market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Getein Biotech, Randox Laboratories, Boditech Med, and LumiraDx. Market players are focusing on research and development, new product launches, and expanding POC offerings. For instance, Abbott’s acquisition of Alere Inc. in 2016 expanded its POC testing portfolio.
Notable developments include Siemens FDA clearance for CardioPhase hs-CRP test (Dec 2022) and Boditech Med MoU for North American market entry (Mar 2022).
Conclusion
The global C-reactive protein testing market is projected to grow from USD 2.55 billion in 2025 to USD 3.95 billion by 2034, supported by rising chronic disease prevalence, increasing adoption of POC tests, and continuous innovation in assay technologies. Despite limitations due to alternative diagnostics, CRP testing remains a vital tool for inflammation monitoring, cardiovascular risk prediction, and improving patient management worldwide.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 4.9% from 2026-2034
Unit Value (USD billion)
Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region
By Product Reagents & Kits
Instruments
By Assay Type Chemiluminescence Immunoassay (CLIA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Immunoturbidimetric Assay
Others
By Detection Range Conventional CRP
hs-CRP
By Setting
Laboratory Testing
Point-of-Care (POC) Testing
By End User Hospitals & Clinics
Diagnostic Laboratories
Others
By Region North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)
- U.S.
- Canada
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Brazil
- Mexico
- Rest of Latin America
- GCC
- South Africa
- Rest of Middle East & Africa
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Pricing Analysis, Key Players, Key Countries/ Regions, 2022/2025
- 4.2. Overview of Regulatory Scenario – For Key Regions/Countries
- 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
- 4.4. Impact of COVID-19 on the Global Healthcare Supply Chain Management Market
- 5. Global Healthcare Supply Chain Management Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast – By Component
- 5.1.1. Software
- 5.1.2. Hardware
- 5.1.3. Services
- 5.2. Market Analysis, Insights and Forecast – By Delivery Mode
- 5.2.1. On-premise
- 5.2.2. Cloud-based
- 5.3. Market Analysis, Insights and Forecast – By End User
- 5.3.1. Healthcare Providers
- 5.3.2. Healthcare Manufacturers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Healthcare Supply Chain Management Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast – By Component
- 6.1.1. Software
- 6.1.2. Hardware
- 6.1.3. Services
- 6.2. Market Analysis, Insights and Forecast – By Delivery Mode
- 6.2.1. On-premise
- 6.2.2. Cloud-based
- 6.3. Market Analysis, Insights and Forecast – By End User
- 6.3.1. Healthcare Providers
- 6.3.2. Healthcare Manufacturers
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Component
- 6.4.2. Canada
- 6.4.2.1. By Component
- 7. Europe Healthcare Supply Chain Management Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast – By Component
- 7.1.1. Software
- 7.1.2. Hardware
- 7.1.3. Services
- 7.2. Market Analysis, Insights and Forecast – By Delivery Mode
- 7.2.1. On-premise
- 7.2.2. Cloud-based
- 7.3. Market Analysis, Insights and Forecast – By End User
- 7.3.1. Healthcare Providers
- 7.3.2. Healthcare Manufacturers
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Component
- 7.4.2. Germany
- 7.4.2.1. By Component
- 7.4.3. France
- 7.4.3.1. By Component
- 7.4.4. Spain
- 7.4.4.1. By Component
- 7.4.5. Italy
- 7.4.5.1. By Component
- 7.4.6. Scandinavia
- 7.4.6.1. By Component
- 7.4.7. Rest of Europe
- 7.4.7.1. By Component
- 8. Asia Pacific Healthcare Supply Chain Management Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast – By Component
- 8.1.1. Software
- 8.1.2. Hardware
- 8.1.3. Services
- 8.2. Market Analysis, Insights and Forecast – By Delivery Mode
- 8.2.1. On-premise
- 8.2.2. Cloud-based
- 8.3. Market Analysis, Insights and Forecast – By End User
- 8.3.1. Healthcare Providers
- 8.3.2. Healthcare Manufacturers
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Component
- 8.4.2. China
- 8.4.2.1. By Component
- 8.4.3. India
- 8.4.3.1. By Component
- 8.4.4. Australia
- 8.4.4.1. By Component
- 8.4.5. Southeast Asia
- 8.4.5.1. By Component
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Component
- 9. Rest of the World Healthcare Supply Chain Management Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast – By Component
- 9.1.1. Software
- 9.1.2. Hardware
- 9.1.3. Services
- 9.2. Market Analysis, Insights and Forecast – By Delivery Mode
- 9.2.1. On-premise
- 9.2.2. Cloud-based
- 9.3. Market Analysis, Insights and Forecast – By End User
- 9.3.1. Healthcare Providers
- 9.3.2. Healthcare Manufacturers
- 9.3.3. Others
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Henry Schein, Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Products & Services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. McKesson Corporation
- 10.2.2.1. Overview
- 10.2.2.2. Products & Services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Oracle
- 10.2.3.1. Overview
- 10.2.3.2. Products & Services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Tecsys Inc.
- 10.2.4.1. Overview
- 10.2.4.2. Products & Services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Banner Health
- 10.2.5.1. Overview
- 10.2.5.2. Products & Services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Global Healthcare Exchange, LLC.
- 10.2.6.1. Overview
- 10.2.6.2. Products & Services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Ascension
- 10.2.7.1. Overview
- 10.2.7.2. Products & Services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Ochsner Health
- 10.2.8.1. Overview
- 10.2.8.2. Products & Services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Cardinal Health
- 10.2.9.1. Overview
- 10.2.9.2. Products & Services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Epicor Software Corporation
- 10.2.10.1. Overview
- 10.2.10.2. Products & Services
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
